Challenges in precision medicine in pancreatic cancer: A focus in cancer stem cells and microbiota
Pancreatic cancer adenocarcinoma (PDAC) is a lethal disease, with the lowest 5-years survival rate of all cancers due to late diagnosis. Despite the advance and success of precision oncology in gastrointestinal cancers, the frequency of molecular-informed therapy decisions in PDAC is currently negle...
Main Authors: | Catalina M. Perelló-Reus, Teresa Rubio-Tomás, Eugenia Cisneros-Barroso, Lesly Ibargüen-González, Juan José Segura-Sampedro, Rafael Morales-Soriano, Carles Barceló |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.995357/full |
Similar Items
-
Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations
by: Anthony Tarabay, et al.
Published: (2023-09-01) -
Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine
by: Bingyu Li, et al.
Published: (2024-09-01) -
Pancreatic cancer tumor organoids exhibit subtype-specific differences in metabolic profiles
by: Hassan A. Ali, et al.
Published: (2024-10-01) -
The Role of Autophagy in Pancreatic Cancer—Recent Advances
by: Maria New, et al.
Published: (2019-12-01) -
Identification of diagnostic markers of pancreatic ductal adenocarcinoma using transcriptomic tumour and blood sample data
by: Aristeidis Sionakidis, et al.
Published: (2023-10-01)